Audit: QRS - Desoxyn for Health & Longevity

Audit conducted on 04/09/2026 15:23 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked across all populated spans: protocol values (ER:394, 404, 408, 416, 418), time-to-effect (ER:174, 451), benefit and risk tier headings (ER:158-310), the 11 avoid-list bullets (ER:358-368), the 10 interaction bullets (ER:336-354), all 10 biomarker rows and the cadence (ER:479-492) and the 7 qualitative markers (ER:496-502) all trace to ER text.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Prolonged prescribed use is untested mirrors the ER’s “remain unstudied over long periods” (ER:145) and “No modern trial has tested this exact medicine at prescribed doses over long periods” (ER:530).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only the brand name “Desoxyn” appears; no PMIDs, author names, NCT identifiers or effect sizes are carried over.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Diffed against the template: the QRS carries the identical set of data-qrs-var names, with marker_#_* expanded to 1-10 and qualitative_item_# expanded to 1-7.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	<span website="evidence_review">, <span website="audit"> and <span website="full_review"> are unchanged; the <style> block and the footer disclaimer are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section carries an empty-state phrasing; Expected Benefits > Speculative is simply blank and > High carries explanatory prose, so item 12.5 (display:none) governs instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Standard labelled protocol, Best time of day and Baseline biomarkers influencing response are the ER’s bold Protocol labels verbatim (ER:394, 404, 416); the 10 marker names match the ER Biomarker column verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names and protocol action labels are verbatim; the time-to-effect labels are descriptive because the ER carries only a single Time to effect bullet (ER:451) with no per-aspect bold label to reuse.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters occur anywhere in the QRS source; the ER’s tier emoji are stripped and tiers are carried by the <strong> labels plus CSS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is already trimmed to bare facts; the remaining volume is the completeness floor imposed by items 8.2, 9.2, 14.2 and 15.2, so no further condensation is available.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration: "00:03" is quoted because the value contains a colon; all other values are unquoted and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	qrs_creation_date: 2026-0904-1453 renders as 09/04/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 11 ER avoid-list bullets are represented as 12 items; the combined “Uncontrolled hypertension … or untreated hyperthyroidism” bullet (ER:362) is split into two.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Preserved: (prior angioedema, anaphylaxis), (<90 days), (>=160/100 mmHg), (eGFR <30 mL/min/1.73 m2), Class III-IV, within 14 days of stopping, unless specialist-managed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications avoid-list uses no ranking notation inside parentheses; only plain thresholds (<90 days, >=160/100 mmHg, <30 mL/min/1.73 m2).
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Contraindications section is not empty (12 items), so no empty-state HTML comment is required.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The absolute MAOI contraindication (ER:334) is correctly carried to Contraindications only; the remaining 10 caution/monitor bullets all appear here.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All parenthetical example drug lists are retained, trimmed of the class names only (e.g. ER “selective serotonin reuptake inhibitors such as sertraline; … venlafaxine” -> “(sertraline, venlafaxine)”).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses; parentheses carry only example drug lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The Key Interactions section is not empty (10 items), so no empty-state HTML comment is required.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard labelled dosing, dose timing, and baseline biomarker correction are the three decision-relevant aspects of the ER Therapeutic Protocol; the competing-approach and origin bullets are commentary rather than actionable steps.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol supplies more than three actionable aspects; all three action sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered Medium-benefit dose titration (ADHD symptom control), Medium-benefit alertness, then Low-benefit appetite suppression, matching the ER benefit tiers.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three time sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (Practical Considerations, ER:451), so the row is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high and benefits_speculative are both set to display: none and emptied, matching the ER’s empty High (ER:154) and Speculative (ER:184) tiers.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER Potential Risks & Side Effects, so no span needs display:none.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 10 rows of the ER biomarker table (ER:483-492) are present with matching targets and rationales.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 7 ER qualitative bullets (ER:496-502) are present.

Issues 04/09/2026 15:23

Pass rate 100.00%. No issues found.

Issues 04/09/2026 15:17

1. 2.7 — Unexpanded “NYHA” acronym: The Contraindications gate at line 571 writes “NYHA Class III–IV heart failure”, introducing an acronym the ER deliberately spells out as “New York Heart Association” (ER line 361) and that the QRS never expands anywhere on the sheet.

Fixes 04/09/2026 15:17

1. 2.7 — Unexpanded NYHA acronym removed: Changed the Contraindications item from “NYHA Class III–IV heart failure” to “Class III–IV heart failure”, dropping the unexplained acronym while preserving the severity class the ER states.

Issues 04/09/2026 15:11

1. 1.3 — Stop-signal threshold strengthened: [qualitative_item_7] (QRS line 842) reads “consecutive nights of reduced sleep with elevated mood”, dropping the ER’s count qualifier (“several consecutive nights”, ER line 502; “three consecutive nights”, ER line 381), which widens the stop trigger beyond what the ER states.

Fixes 04/09/2026 15:11

1. 1.3 — Stop-signal night count restored: [qualitative_item_7] changed from “consecutive nights of reduced sleep with elevated mood” to “several consecutive nights of reduced sleep with elevated mood”, matching the ER’s wording at line 502.

Issues 04/09/2026 15:05

1. 4.5 — Sheet overruns one A4 page: At the sheet’s own type sizes the populated QRS runs roughly 1.8× the printable height of one A4 page; the Protocol and Time-to-effect sub cells, the At-A-Glance block, the Monitoring cadence sentence and several stop_items, caution_items and qualitative_item_* entries carry more words than the per-section budget allows.

Fixes 04/09/2026 15:05

1. 4.5 — At-A-Glance tightened: Merged the two closing sentences of at_a_glance into one and replaced “adult use sits outside the label” with “all adult use is off the label”, saving a rendered line without dropping any fact.
2. 4.5 — Protocol sub-cells condensed: Shortened action_1_sub (“increased in 5 mg steps at weekly intervals to a labelled range of 20–25 mg daily” → “in 5 mg weekly steps to a labelled 20–25 mg daily”), action_2_sub and action_3_sub, removing one to two wrapped lines from each of the three protocol cells.
3. 4.5 — Time-to-effect sub-cells condensed: Trimmed time_1_sub and time_2_sub to single-clause statements and removed the trailing “while cardiovascular effects do not habituate” elaboration from time_3_sub.
4. 4.5 — Contraindication items shortened: Rewrote all twelve stop_items to their key fact (e.g. “Hypersensitivity to amphetamine or any tablet component” → “Amphetamine hypersensitivity”; “New York Heart Association Class III–IV” → “NYHA Class III–IV”), keeping every item and every threshold, time window and severity qualifier.
5. 4.5 — Interaction items shortened: Condensed the class labels in caution_items (“Supplements with additive effects on serotonin or catecholamines” → “Serotonergic or catecholaminergic supplements”, “Tricyclic antidepressants” → “Tricyclics”), retaining all ten items and their full named-example lists.
6. 4.5 — Monitoring cadence compressed: Recast monitoring_cadence from four sentences into one semicolon-separated sentence, preserving every interval stated in the ER.
7. 4.5 — Qualitative items trimmed: Removed redundant wording from qualitative_item_1, _2, _4 and _7 (e.g. “the earliest and most sensitive signal” → “the earliest signal”) while keeping all seven markers and their stop-signal framing.

Issues 04/09/2026 14:58

1. 4.2 / 4.3 — Protocol label not ER verbatim: [action_3_label] at line 478 reads “Baseline correction before titration”, an invented label; the corresponding ER bullet’s bold label is “Baseline biomarkers influencing response:” (ER line 416).

Fixes 04/09/2026 14:58

1. 4.2 / 4.3 — Protocol label restored to ER wording: [action_3_label] at line 478 was changed from the invented “Baseline correction before titration” to the ER bullet’s verbatim bold label “Baseline biomarkers influencing response”.